Related references
Note: Only part of the references are listed.Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: The LACunar Intervention-1 (LACI-1) trial, a randomised clinical trial
Gordon W. Blair et al.
ECLINICALMEDICINE (2019)
Preventing cognitive decline and dementia from cerebral small vessel disease: The LACI-1 Trial. Protocol and statistical analysis plan of a phase IIa dose escalation trial testing tolerability, safety and effect on intermediary endpoints of isosorbide mononitrate and cilostazol, separately and in combination
Gordon W. Blair et al.
INTERNATIONAL JOURNAL OF STROKE (2018)
Blood-brain barrier failure as a core mechanism in cerebral small vessel disease and dementia: evidence from a cohort study
Joanna M. Wardlaw et al.
ALZHEIMERS & DEMENTIA (2017)
Remote Assessment of Platelet Function in Patients with Acute Stroke or Transient Ischaemic Attack
Philip M. Bath et al.
STROKE RESEARCH AND TREATMENT (2017)
Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions
Philip M. Bath et al.
INTERNATIONAL JOURNAL OF STROKE (2015)
Blood Markers of Coagulation, Fibrinolysis, Endothelial Dysfunction and Inflammation in Lacunar Stroke versus Non-Lacunar Stroke and Non-Stroke: Systematic Review and Meta-Analysis
Stewart Wiseman et al.
CEREBROVASCULAR DISEASES (2014)
Share Paper
